In The News: Department of Brain Health
As the population ages and the demands of caregiving increase, discussions about caregiver wellness and brain health are gaining momentum nationwide. Approximately 38 million individuals across the country undertake the vital role of family caregivers, providing support for parents, spouses, adult children with disabilities, and other loved ones. Yet, the emotional and physical strains of caregiving cannot be understated.
Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.
Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.
The team from the Department of Brain Health at 51³Ô¹ÏºÚÁÏ is scheduled to discuss the latest advancements in the care and treatment of people with brain disorders.
About 38 million Americans are caregivers for parents, spouses, adult children with disabilities, friends and other loved ones.
Most ARIA cases are mild, but some have been fatal
Recently approved disease-modifying treatments for Alzheimer's disease have created a sudden demand, but these and other drugs in the pipeline are not for all patients with clinical Alzheimer's symptoms, experts said.
Looking ahead to 2024 and beyond: "There is so much more to be done"
Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.
After decades of failed trials, ineffective drugs and billions of dollars spent, a new frontier of shots offer a glimmer of hope for current and future sufferers of the cruel condition that affects 5.8million Americans.
The positive results are expected to form the basis for further development of Lomecel-B as a potential treatment for mild AD
Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial